148 related articles for article (PubMed ID: 31703065)
1. Coadministration of kla peptide with HPRP-A1 to enhance anticancer activity.
Hao W; Hu C; Huang Y; Chen Y
PLoS One; 2019; 14(11):e0223738. PubMed ID: 31703065
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effect of the pro-apoptosis peptide kla-TAT and the cationic anticancer peptide HPRP-A1.
Hu C; Chen X; Huang Y; Chen Y
Apoptosis; 2018 Feb; 23(2):132-142. PubMed ID: 29397453
[TBL] [Abstract][Full Text] [Related]
3. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation.
Hu C; Huang Y; Chen Y
Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of iRGD with peptide HPRP-A1 to improve anticancer activity and membrane penetrability.
Hu C; Chen X; Huang Y; Chen Y
Sci Rep; 2018 Feb; 8(1):2274. PubMed ID: 29396568
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of kla-TAT peptide and iRGD to enhance the permeability on A549 3D multiple sphere cells and accumulation on xenograft mice.
Hu C; Chen X; Huang Y; Chen Y
Chem Biol Drug Des; 2018 Aug; 92(2):1567-1575. PubMed ID: 29722179
[TBL] [Abstract][Full Text] [Related]
6. Anticancer activity of Helicobacter pylori ribosomal protein (HPRP) with iRGD in treatment of colon cancer.
Yaghoubi A; Asgharzadeh F; Movaqar A; Ghazvini K; Hassanian SM; Avan A; Khazaei M; Soleimanpour S
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2851-2865. PubMed ID: 34117917
[TBL] [Abstract][Full Text] [Related]
7. TAT Modification of Alpha-Helical Anticancer Peptides to Improve Specificity and Efficacy.
Hao X; Yan Q; Zhao J; Wang W; Huang Y; Chen Y
PLoS One; 2015; 10(9):e0138911. PubMed ID: 26405806
[TBL] [Abstract][Full Text] [Related]
8. A proapoptotic peptide conjugated to penetratin selectively inhibits tumor cell growth.
Alves ID; Carré M; Montero MP; Castano S; Lecomte S; Marquant R; Lecorché P; Burlina F; Schatz C; Sagan S; Chassaing G; Braguer D; Lavielle S
Biochim Biophys Acta; 2014 Aug; 1838(8):2087-98. PubMed ID: 24796502
[TBL] [Abstract][Full Text] [Related]
9. A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity.
Law B; Quinti L; Choi Y; Weissleder R; Tung CH
Mol Cancer Ther; 2006 Aug; 5(8):1944-9. PubMed ID: 16928814
[TBL] [Abstract][Full Text] [Related]
10. Multivalent display of pendant pro-apoptotic peptides increases cytotoxic activity.
Chu DS; Bocek MJ; Shi J; Ta A; Ngambenjawong C; Rostomily RC; Pun SH
J Control Release; 2015 May; 205():155-61. PubMed ID: 25596326
[TBL] [Abstract][Full Text] [Related]
11. The synergistic effect of chimeras consisting of N-terminal smac and modified KLA peptides in inducing apoptosis in breast cancer cell lines.
Tavakoli S; Firoozpour L; Davoodi J
Biochem Biophys Res Commun; 2023 May; 655():138-144. PubMed ID: 36934589
[TBL] [Abstract][Full Text] [Related]
12. Enhanced antitumor effects of the BRBP1 compound peptide BRBP1-TAT-KLA on human brain metastatic breast cancer.
Fu B; Long W; Zhang Y; Zhang A; Miao F; Shen Y; Pan N; Gan G; Nie F; He Y; Zhang J; Teng G
Sci Rep; 2015 Jan; 5():8029. PubMed ID: 25619721
[TBL] [Abstract][Full Text] [Related]
13. Apoptosis inducing, conformationally constrained, dimeric peptide analogs of KLA with submicromolar cell penetrating abilities.
Hyun S; Lee S; Kim S; Jang S; Yu J; Lee Y
Biomacromolecules; 2014 Oct; 15(10):3746-52. PubMed ID: 25188534
[TBL] [Abstract][Full Text] [Related]
14. Bladder tumor-targeted delivery of pro-apoptotic peptide for cancer therapy.
Jung HK; Kim S; Park RW; Park JY; Kim IS; Lee B
J Control Release; 2016 Aug; 235():259-267. PubMed ID: 27282414
[TBL] [Abstract][Full Text] [Related]
15. Two hits are better than one: synergistic anticancer activity of α-helical peptides and doxorubicin/epirubicin.
Zhao J; Huang Y; Liu D; Chen Y
Oncotarget; 2015 Jan; 6(3):1769-78. PubMed ID: 25593197
[TBL] [Abstract][Full Text] [Related]
16. Overcoming drug-resistant lung cancer by paclitaxel loaded dual-functional liposomes with mitochondria targeting and pH-response.
Jiang L; Li L; He X; Yi Q; He B; Cao J; Pan W; Gu Z
Biomaterials; 2015 Jun; 52():126-39. PubMed ID: 25818419
[TBL] [Abstract][Full Text] [Related]
17. Two birds, one stone: dual targeting of the cancer cell surface and subcellular mitochondria by the galectin-3-binding peptide G3-C12.
Sun W; Li L; Li LJ; Yang QQ; Zhang ZR; Huang Y
Acta Pharmacol Sin; 2017 Jun; 38(6):806-822. PubMed ID: 28065935
[TBL] [Abstract][Full Text] [Related]
18. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
19. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice.
Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z
Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766
[TBL] [Abstract][Full Text] [Related]
20. Stimuli-Responsive Conformational Transformation of Peptides for Tunable Cytotoxicity.
Lee J; Oh ET; Lee H; Kim J; Kim HG; Park HJ; Kim C
Bioconjug Chem; 2020 Jan; 31(1):43-50. PubMed ID: 31841634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
